GH 509
Alternative Names: GH-509Latest Information Update: 26 Apr 2023
At a glance
- Originator 1Globe Biomedical
- Class Hepatoprotectants
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis
Most Recent Events
- 28 Feb 2023 Phase-I/II clinical trials in Non-alcoholic fatty liver disease in China (PO) (NCT05784779)
- 28 Feb 2023 Phase-I/II clinical trials in Non-alcoholic steatohepatitis in China (PO) (NCT05784779)